REVerse Intestinal Metaplasia in the Stomach (REVISE)
Therapeutic Intervention to Reverse Gastric Precancer
Katherine Garman
32 participants
Dec 15, 2025
INTERVENTIONAL
Conditions
Summary
This study is designed to test the use of Pyrvinium vs placebo as a treatment for gastric intestinal metaplasia with features associated with increased risk of cancer. Response will be determined by assessing the extent and quality of the gastric intestinal metaplasia before and after treatment. A secondary aim will be to generate gastric organoids from patient-derived samples to test the effects of pyrvinium in vitro in patient-derived samples, and also to identify new drugs that may help reverse gastric intestinal metaplasia.
Eligibility
Inclusion Criteria3
- Adults (including men, women, and non-binary individuals) over age 18 with known GIM with at least one high-risk feature (extensive vs limited, incomplete or mixed-type GIM, family history of stomach cancer),
- Ability to provide informed consent,
- Evidence of prior but not active H. pylori infection
Exclusion Criteria3
- Active gastric cancer diagnosis,
- High-risk of bleeding complications due to anticoagulants or underlying medical condition,
- Pregnancy (which is a contraindication to non-emergent endoscopy due to anesthesia risks)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Pyrvinium (2 mg/kg) per day for 14 days
Placebo for 14 days
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06590454